CHEST: American College of Chest Physicians Annual Meeting

Experts at CHEST 2025 highlight rising costs, insurance complexity, and workforce shortages as major barriers to health care access in the US.

Vaccine awareness, safety, and addressing misinformation are all important to improve adherence and public health outcomes, said Kristina Crothers, MD.

Panels held throughout the conference emphasized both how far the specialization has come but also how far it has yet to go.

Dedicated COPD respiratory therapists can improve inhaler use, ensure adherence, and bridge care transitions, explained Megan Dulohery Scrodin, MD.

Meta-analyses presented at the CHEST 2025 Annual Meeting find that combinations that include amivantamab and nivolumab improved overall and progression-free survival in non–small cell lung cancer (NSCLC).

Digitized behavioral cough suppression therapy is a safe, highly effective, and accessible alternative to drugs for chronic cough, said Laurie Slovarp, PhD.

The efficacy of GLP-1 inhibitors in weight loss has introduced them as a means of also addressing obstructive sleep apnea in sleep medicine.

A session held during the CHEST 2025 Annual Meeting focused on the North American guidelines for treating bronchiectasis.

CT scans can play a role not just in diagnosing but also in monitoring non–cystic fibrosis bronchiectasis management, explained James D. Chalmers, MD.

Inhaled corticosteroids pose long-term risks in COPD management, prompting careful screening and potential de-escalation strategies, said Sara Assaf, MD.

Counseling patients with obstructive sleep apnea on using GLP-1s effectively prior to starting treatment can help ensure adherence, said Matthew Biszewski, PharmD.

Phenotyping patients can help to identify potential heart failure with preserved ejection fraction (HFpEF) as well as improve patient outcomes.

Intensivists gathered at the CHEST 2025 Annual Meeting to discuss how climate change is affecting and will affect their practice of treating pulmonary conditions.

Results from the ASPEN trial also show that brensocatib displayed several benefits when used in patients with bronchiectasis, including a reduction in symptom burden.

Panels at the conference include coverage of new guidelines, the use of AI in pulmonary care, and progress on respiratory vaccines.

The top 5 most-viewed content from CHEST 2024 included expert interviews and coverage on multiple areas of chest medicine.

In part 2 of our interview, Cesar Davila-Chapa, MD, discusses key findings, limitations, and future research directions from his study on racial disparities in idiopathic pulmonary fibrosis (IPF) outcomes.

Research presented at CHEST 2024 examined the effect of steroid choice on individuals who have a dual diagnosis of heart failure and chronic obstructive pulmonary disease (COPD).

Global respiratory leaders at the CHEST 2024 annual meeting underscored the ongoing clinical burden of tuberculosis, emphasizing that it remains a significant global health challenge that requires ongoing attention and awareness.

Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.

Two posters presented at the CHEST 2024 annual meeting highlighted the importance of addressing socioeconomic disparities and identifying clinical predictors to improve outcomes and survival rates among patients with idiopathic pulmonary fibrosis (IPF).

Two posters presented at the CHEST 2024 annual meeting highlighted significant disparities in acute coronary syndrome care and outcomes among different racial, ethnic, and gender groups, underscoring the urgent need for targeted interventions to address these inequities.

At CHEST 2024, Cesar Davila-Chapa, MD, University of Nebraska Medical Center, brings awareness to the racial disparities demonstrated in his investigation of idiopathic pulmonary fibrosis (IPF) hospitalizations and outcomes.

Two posters at the CHEST 2024 annual meeting revealed that 18% of eligible patients hospitalized with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) participated in post-discharge pulmonary rehabilitation (PR), with ineligibility significantly limiting uptake.

One of the key highlights was the discussion of Pulmonary Embolism Response Teams (PERT), addressing controversies in PE management and focusing on personalized, patient-centered care.

Two posters presented at CHEST 2024 revealed significant racial and ethnic disparities in the hospitalization and treatment of patients with idiopathic pulmonary fibrosis (IPF), with Black patients hospitalized at younger ages but less likely to receive antifibrotic medications than White patients.

Posters presented at the CHEST 2024 annual meeting demonstrated air pollution's role in lung impairment and disease, highlighting the urgent need for providers to address the escalating impacts of climate change on lung health.

During CHEST 2024, Maxine Dexter, MD, Kaiser Permanente, discussed her belief in the vital role of physicians in public health advocacy, drawing from her legislative work on issues as a former Oregon State Representative.

CHEST 2024 late-breaking data showcased the potential of AI-based systems in diagnosing and managing pulmonary embolism.

Two posters presented at the CHEST 2024 annual meeting underscore the importance of early identification and treatment of chronic obstructive pulmonary disease (COPD), with better adherence and outcomes among those using single-inhaler triple therapy.